The evolving clinical profile of abatacept (CTLA4-lg): A novel co-stimulatory modulator for the treatment of rheumatoid arthritis

Eric M. Ruderman*, Richard M. Pope

*Corresponding author for this work

Research output: Contribution to journalReview article

74 Scopus citations

Abstract

Abatacept (CTLA4-Ig) is a novel fusion protein designed to modulate the T cell co-stimulatory signal mediated through the CD28-CD80/86 pathway. Clinical trials have provided preliminary evidence of the efficacy of this compound in the treatment of rheumatoid arthritis. This review describes the molecular and biologic bases for the use of abatacept in rheumatoid arthritis and summarizes the current clinical data on its safety and effectiveness in this disease.

Original languageEnglish (US)
Pages (from-to)S21-S25
JournalArthritis Research and Therapy
Volume7
Issue numberSUPPL. 2
DOIs
StatePublished - Mar 2005

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'The evolving clinical profile of abatacept (CTLA4-lg): A novel co-stimulatory modulator for the treatment of rheumatoid arthritis'. Together they form a unique fingerprint.

  • Cite this